Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Clinical validity and utility of tumor-infiltrating
lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front
Oncol. 2017. doi:10.3389/fonc.2017.00156.
Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting
factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4(5):522-526.
Hegde PS, Karanikas V, Evers S, et al. The where, the when, and the how of immune monitoring for cancer
immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865-1874.
Masucci GV, Cesano A, Hawtin R, et al. Validation of biomarkers to predict response to immunotherapy in
cancer: Volume I—pre-analytical and analytical validation. J Immunother Cancer. 2016;4:76.
Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for
PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47.